🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522204-24-00
Completed Phase II

J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

2025-522204-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
Eli Lilly & Co.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
23/02/2026
Enrollment target
77
Sites
Romania, Spain, France, Italy

Condition studied

Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions, Nausea

Investigational medicinal product(s)

0.9% sodium chlorideGRANISETRONPALONOSETRONCOMBINATIONSAPREPITANTDEXAMETHASONEPALONOSETRONONDANSETRONLagipra

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV CR defined as no vomiting and no rescue medication

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522204-24-00 on CTIS ↗ ← All trials in the EU